Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Trellus Health PLC ( (GB:TRLS) ) just unveiled an announcement.
Trellus Health has signed a master services agreement with Gastro Health, a leading U.S. clinical trial site network, to deploy its TrialSet engagement tools to support site performance and jointly market each party’s services. While not immediately revenue-generating, the agreement broadens Trellus’s access to potential pharmaceutical and clinical partners and further validates its differentiated digital platform in the clinical trial ecosystem.
The company is also in advanced talks on another clinical trial collaboration, while extending its cash runway through ongoing cost reductions that have brought monthly cash burn to about $300,000 and are expected to sustain operations into early April 2026. The board is exploring a range of funding options, including a potential director loan and an existing but currently constrained convertible facility, underscoring both the company’s capital needs and its commitment to progressing its commercial strategy.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on TRLS Stock
According to Spark, TipRanks’ AI Analyst, TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that delivers Trellus Elevate, a digital, resilience-based platform combining data analytics, technology tools and expert coaching to support self-management of complex chronic conditions. The company initially targets high-cost gastrointestinal diseases such as inflammatory bowel disease, aiming to cut hospitalisations, reduce emergency visits and improve long-term outcomes for patients and payers.
Using its proprietary methodology, Trellus Health supplies value-based solutions to both patients and pharmaceutical partners, including Trellus TrialSet, which supports clinical trials and commercialisation with engagement tools to boost adherence and trial success. Founded by Mount Sinai clinicians with decades of experience in whole-person IBD care, the company listed on AIM in 2021 and sees broad applicability of its platform across multiple chronic conditions and therapeutic areas.
Average Trading Volume: 7,672,784
Technical Sentiment Signal: Sell
Current Market Cap: £752.5K
For an in-depth examination of TRLS stock, go to TipRanks’ Overview page.